NRx Pharmaceuticals signs agreement with Columbia University

NRx Pharmaceuticals announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression. This represents NRx’s second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication. NRx plans to present the data from these two trials to FDA in support of a New Drug Application to be filed in Q1 of 2024.